While we do our best to interpret variants using the literature and a variety of databases, this can be challenging when the scientific data are limited or conflicting. The limitations of exome sequencing are the same as mtDNA sequencing and deletion test is expected to detect greater than 98% of known pathogenic mutations and deletions of the mitochondrial genome. Very low levels of heteroplasmy may be missed with this test. Same as XomeDx. Because the analysis for XomeDx Slice is targeted, variants present in genes not included on the pre-selected gene list will not be identified or of any given gene not covered by whole exome sequencing will not be filled in with Sanger sequencing.
An elevation in serum bilirubin level of more than 2 times ULN with associated transaminase rise is an ominous sign. This indicates severe hepatotoxicity and is likely to lead to mortality in 10% to 15% of patients, especially if the offending drug is not stopped ( Hy's Law ).   This is because it requires significant damage to the liver to impair bilirubin excretion, hence minor impairment (in the absence of biliary obstruction or Gilbert syndrome ) would not lead to jaundice. Other poor predictors of outcome are old age, female sex, high AST .  
Injectable steroids are injected into muscle tissue, not into the veins. They are slowly released from the muscles into the rest of the body, and may be detectable for months after last use. Injectable steroids can be oil-based or water-based. Injectable anabolic steroids which are oil-based have longer half-life than water-based steroids. Both steroid types have much longer half-lives than oral anabolic steroids. And this is proving to be a drawback for injectables as they have high probability of being detected in drug screening since their clearance times tend to be longer than orals. Athletes resolve this problem by using injectable testosterone early in the cycle then switch to orals when approaching the end of the cycle and drug testing is imminent.